121 related articles for article (PubMed ID: 31709648)
1. The presence of two reduced function variants in CYP2C9 influences the acute response to glipizide.
Chen L; Li JH; Kaur V; Muhammad A; Fernandez M; Hudson MS; Goldfine AB; Florez JC
Diabet Med; 2020 Dec; 37(12):2124-2130. PubMed ID: 31709648
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide association analysis identifies ancestry-specific genetic variation associated with acute response to metformin and glipizide in SUGAR-MGH.
Li JH; Brenner LN; Kaur V; Figueroa K; Schroeder P; Huerta-Chagoya A; ; ; Udler MS; Leong A; Mercader JM; Florez JC
Diabetologia; 2023 Jul; 66(7):1260-1272. PubMed ID: 37233759
[TBL] [Abstract][Full Text] [Related]
3. The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes.
Walford GA; Colomo N; Todd JN; Billings LK; Fernandez M; Chamarthi B; Warner AS; Davis J; Littleton KR; Hernandez AM; Fanelli RR; Lanier A; Barbato C; Ackerman RJ; Khan SQ; Bui R; Garber L; Stolerman ES; Moore AF; Huang C; Kaur V; Harden M; Taylor A; Chen L; Manning AK; Huang P; Wexler D; McCarthy RM; Lo J; Thomas MK; Grant RW; Goldfine A; Hudson MS; Florez JC
PLoS One; 2015; 10(3):e0121553. PubMed ID: 25812009
[TBL] [Abstract][Full Text] [Related]
4.
Srinivasan S; Kaur V; Chamarthi B; Littleton KR; Chen L; Manning AK; Merino J; Thomas MK; Hudson M; Goldfine A; Florez JC
Diabetes Care; 2018 Mar; 41(3):554-561. PubMed ID: 29326107
[TBL] [Abstract][Full Text] [Related]
5. Effects of CYP2C9*3 and *13 alleles on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects.
Kim NT; Cho CK; Kang P; Park HJ; Lee YJ; Bae JW; Jang CG; Lee SY
Arch Pharm Res; 2022 Feb; 45(2):114-121. PubMed ID: 34952963
[TBL] [Abstract][Full Text] [Related]
6. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
Carroll MF; Izard A; Riboni K; Burge MR; Schade DS
Diabetes Care; 2002 Dec; 25(12):2147-52. PubMed ID: 12453952
[TBL] [Abstract][Full Text] [Related]
7. Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis.
Yee J; Heo Y; Kim H; Yoon HY; Song G; Gwak HS
Clin Ther; 2021 May; 43(5):836-843.e4. PubMed ID: 33840516
[TBL] [Abstract][Full Text] [Related]
8. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
[TBL] [Abstract][Full Text] [Related]
9. The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy.
Saberi M; Ramazani Z; Rashidi H; Saberi A
Vasc Health Risk Manag; 2020; 16():241-248. PubMed ID: 32606720
[TBL] [Abstract][Full Text] [Related]
10. CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients.
Klen J; Dolžan V; Janež A
Eur J Clin Pharmacol; 2014 Apr; 70(4):421-8. PubMed ID: 24442125
[TBL] [Abstract][Full Text] [Related]
11. The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects.
Tan B; Zhang YF; Chen XY; Zhao XH; Li GX; Zhong DF
Eur J Clin Pharmacol; 2010 Feb; 66(2):145-51. PubMed ID: 19847408
[TBL] [Abstract][Full Text] [Related]
12. OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide.
Yang F; Liu L; Chen L; Liu M; Liu F; Xiong Y; Hu X; Xia C
Sci Rep; 2018 Dec; 8(1):18063. PubMed ID: 30584236
[TBL] [Abstract][Full Text] [Related]
13. Effect of glipizide treatment on response to an infused glucose load in patients with NIDDM.
Sheu WH; Jeng CY; Fuh MM; Chen YD; Reaven GM
Diabetes Care; 1995 Dec; 18(12):1582-7. PubMed ID: 8722055
[TBL] [Abstract][Full Text] [Related]
14. Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM.
Riddle MC; McDaniel PA; Tive LA
Diabetes Care; 1997 Jun; 20(6):992-4. PubMed ID: 9167112
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers.
Kirchheiner J; Brockmöller J; Meineke I; Bauer S; Rohde W; Meisel C; Roots I
Clin Pharmacol Ther; 2002 Apr; 71(4):286-96. PubMed ID: 11956512
[TBL] [Abstract][Full Text] [Related]
16. The effect of glipizide gastrointestinal therapeutic system on islet cell hormonal responses to a test meal in NIDDM.
Mooradian AD; Albert SG; Bernbaum M; Plummer S
Diabetes Care; 1996 Aug; 19(8):883-4. PubMed ID: 8842609
[TBL] [Abstract][Full Text] [Related]
17. Probable hypoglycemic adverse drug reaction associated with prickly pear cactus, glipizide, and metformin in a patient with type 2 diabetes mellitus.
Sobieraj DM; Freyer CW
Ann Pharmacother; 2010; 44(7-8):1334-7. PubMed ID: 20516361
[TBL] [Abstract][Full Text] [Related]
18. Long-term beneficial effects of glipizide treatment on glucose tolerance in subjects with impaired glucose tolerance.
Eriksson JG; Lehtovirta M; Ehrnström B; Salmela S; Groop L
J Intern Med; 2006 Jun; 259(6):553-60. PubMed ID: 16704555
[TBL] [Abstract][Full Text] [Related]
19. CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients.
Zeng W; Guo Y; Chen P; Liu Z; Chen D; Han C
J Diabetes Investig; 2016 Sep; 7(5):764-8. PubMed ID: 27181593
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
